Core Insights - Bavarian Nordic A/S reported preliminary financial results for 2025, with revenue of DKK 6,244 million, exceeding the latest guidance of approximately DKK 6,000 million [1][2] - The company achieved an EBITDA of DKK 2,542 million, resulting in an EBITDA margin of 41%, surpassing the latest guidance of approximately 40% [2][4] Financial Performance - Revenue breakdown for 2025 includes DKK 3,105 million from Public Preparedness and DKK 2,963 million from Travel Health, with Travel Health showing a 30% year-over-year growth [5][7] - The company’s core vaccines, rabies and TBE, contributed significantly to the revenue growth, with respective increases of 34% and 20% [5] - The chikungunya vaccine generated DKK 85 million in its first year of sales, exceeding guidance by DKK 10 million [5] 2026 Financial Guidance - For 2026, Bavarian Nordic expects revenue between DKK 5,000 million and DKK 5,200 million, with an EBITDA margin of approximately 25% [6][7] - Revenue from Public Preparedness is anticipated to be between DKK 1,800 million and DKK 2,000 million, with DKK 1,300 million already secured through contracts [8] - Travel Health revenue is projected at approximately DKK 3,000 million, reflecting a 10% growth over the prior year [9][10] Research and Development - R&D spending for 2026 is capped at DKK 750 million, focusing on life-cycle management of the commercial portfolio and additional studies for the chikungunya vaccine [11] - Early-stage pipeline assets are expected to enter clinical development in 2027 [11] Capital Expenditure - CAPEX for 2026 is expected to be around DKK 250 million, with inventory levels anticipated to remain relatively unchanged [12]

Core Insights - Beach Cities Commercial Bank reported its financial results for the fourth quarter of 2025, highlighting robust growth and a focus on sustainable profitability [1] Financial Performance - The bank's net loss for Q4 2025 was $117.6k, a decrease from a profit of $14.5k in Q3 2025, but adjusted net income was $22.4k when excluding credit provisions [1] - Year-to-date loss for 2025 was $605.7k, significantly reduced by 87% from a loss of $4.5 million in 2024 [1] - Total deposits reached $143.5 million, marking a 9% increase from Q3 2025 and a 27% increase year-over-year [1] - Gross loans amounted to $144.1 million, reflecting a 12% growth from Q3 2025 and a 36% increase from the previous year [1] - Total assets grew to $176.7 million, a 13% increase from Q3 2025 and a 35% increase year-over-year [1] Asset Quality and Liquidity - The bank maintained a reserve for credit losses of $1.412 million, equating to 0.98% of total loans, with no delinquent or non-performing assets reported [1] - Total liquidity was high at $28.3 million, representing 16.02% of total assets, with additional contingent borrowing sources of $18.7 million [1] Interest Income and Expenses - Total interest income for Q4 2025 was $2.87 million, a 2.2% increase from Q3 2025, while interest expense decreased by 6.1% to $1.17 million [1] - The bank's net interest margin stood at 3.82% as of December 31, 2025, supported by an average loan yield of 7.69% [1] Operational Efficiency - Total operating expenses for Q4 2025 were $1.62 million, a 4.8% increase from Q3 2025, with a decrease in salaries and benefits expenses [1] - The bank's non-interest income from loan sales increased by 277% year-over-year, although gains from loan sales in Q4 2025 were lower than in Q3 2025 due to external factors [1] Future Outlook - The bank plans to raise up to $5 million through a private placement offering to support its growth momentum [1] - The appointment of a new President/CEO is expected to further enhance the bank's strategic direction and operational capabilities [1]

Core Insights - Service Corporation International (SCI) reported a strong financial performance for Q4 2025, with adjusted earnings per share (EPS) growing 8% year-over-year to $1.14 and a full-year adjusted EPS increase of 9% to $3.85 [1][2] - The company generated $966 million in adjusted operating cash flow for the full year, enabling strategic investments and returning $645 million to shareholders through dividends and share repurchases [1][2] - Looking ahead to 2026, SCI anticipates adjusted EPS growth within the long-term target range of 8% to 12% [2] Financial Performance - Q4 2025 revenue increased by $19 million, or 2%, to $1,111.5 million compared to Q4 2024, with full-year revenue rising by $123 million, or 3%, to $4,309.2 million [1][3] - Gross profit for Q4 2025 was $311.7 million, a 2% increase from Q4 2024, while full-year gross profit rose by $49 million, or 5%, to $1,140.1 million [1][3] - Net cash provided by operating activities decreased by $51.2 million to $212.9 million in Q4 2025, primarily due to higher cash interest and taxes [1][3] Segment Performance - Comparable preneed cemetery sales production grew by 2% in Q4 2025, with a full-year increase of $48 million, or 4% [1][5] - Comparable total funeral sales average increased by 3% in Q4 2025, while comparable preneed funeral sales production surged by 11% [1][5] - The company experienced a 0.9% increase in comparable cemetery revenue, driven by higher other revenue, despite a decline in core revenue [6] Capital Expenditures and Investments - In 2025, SCI invested approximately $101 million in acquisitions of 22 funeral homes and 2 cemeteries, alongside $79 million in real estate and new construction [1][2] - Total capital expenditures for 2025 amounted to $388.6 million, reflecting a $19.5 million increase from the previous year [6][7] Outlook for 2026 - The 2026 outlook for diluted EPS excluding special items is projected to be between $4.05 and $4.35, with net cash provided by operating activities expected to range from $1,005 million to $1,065 million [2][3] - Capital improvements at existing locations are budgeted at $135 million, with cemetery property development at $165 million [2][3]

State Bank of India is set to announce its financial results for the third quarter ended Dec. 31, 2025, later this week. The bank confirmed the schedule in a filing with the stock exchanges. SBI is the largest banking and financial services organisation in India, with an asset base of over Rs 61 trillion. The bank serves over 50 crore customers through its vast network of over 23,085 branches, 63,580 ATMs/ADWMs, 82,900 BC outlets.SBI Q3 Results: DateState Bank of India has announced that its Central Board w ...

Financial Results Schedule - The company will publish its unaudited results for Q4 2025 and the full year 2025 on 06 February 2026 [1] - Audited results for 2025, along with a dividend proposal and agenda for the Annual General Meeting of Shareholders, will be released on 27 March 2026 [1] - Financial results for Q1 2026 are scheduled for 08 May 2026 [1] - Financial results for Q2 2026 will be published on 31 July 2026 [1] - The company will announce its financial results for Q3 2026 on 30 October 2026 [1] Annual General Meeting - The Annual General Meeting of Shareholders is set to take place on 23 April 2026 [1]

Core Viewpoint - Micron Technology reported record financial results for Q1 fiscal 2026, exceeding analysts' expectations, which has led to a significant increase in its stock price in after-hours trading [1][2]. Financial Performance - Micron achieved revenue of $13.64 billion in Q1 2026, marking a 56.7% year-over-year increase, surpassing analysts' expectations of $12.88 billion [4]. - The cloud memory business unit was the largest contributor to growth, generating $5.28 billion in sales, which represents a 99.5% increase compared to Q1 fiscal 2025 [4]. - Adjusted diluted earnings per share (EPS) were reported at $4.78, exceeding the estimated EPS of $3.94 [6]. - The company reported a record free cash flow of $3.9 billion, surpassing its previous record from Q4 2018 by over 20% [7]. Future Projections - Management projected Q2 2026 revenue between $18.3 billion and $19.1 billion, with adjusted diluted EPS expected to be between $8.22 and $8.62 [8].

Core Insights - Victoria's Secret & Co reported better-than-expected third-quarter financial results, with losses of 27 cents per share compared to the analyst consensus estimate of 59 cents per share, and quarterly sales of $1.472 billion exceeding the estimate of $1.410 billion [1] - The company raised its FY2025 adjusted EPS guidance from $1.80-$2.20 to $2.40-$2.65 and increased its sales guidance from $6.330 billion-$6.410 billion to $6.450 billion-$6.480 billion [2] - CEO Hillary Super highlighted a 9% increase in net sales year-over-year, driven by strong performance across Victoria's Secret, PINK, and Beauty, and expressed confidence in the company's outlook for the holiday season [3] Financial Performance - Quarterly losses were reported at 27 cents per share, beating the consensus estimate of 59 cents [1] - Quarterly sales reached $1.472 billion, surpassing the analyst consensus estimate of $1.410 billion [1] - Net sales increased by 9% compared to the previous year [3] Guidance Updates - FY2025 adjusted EPS guidance was raised to $2.40-$2.65 from $1.80-$2.20 [2] - FY2025 sales guidance was increased to $6.450 billion-$6.480 billion from $6.330 billion-$6.410 billion [2] Analyst Reactions - Telsey Advisory Group maintained a Market Perform rating and raised the price target from $45 to $50 [6] - UBS maintained a Buy rating and increased the price target from $46 to $60 [6] - Goldman Sachs maintained a Neutral rating and raised the price target from $32 to $47 [6]

Core Viewpoint - Arrow Exploration Corp. has reported its Q3 2025 financial results, highlighting significant operational activities and production growth in Colombia, alongside ongoing discussions for regulatory approvals related to its assets [1][2][7]. Financial Highlights - Total oil and natural gas revenue for Q3 2025 was $18.5 million, with a year-to-date (YTD) revenue of $53.9 million [8][9]. - The company recorded a net income of $3.1 million for Q3 2025, with a YTD net income of $4.8 million [9][12]. - Cash balance as of November 1, 2025, was $8.2 million, reflecting significant capital expenditures in Q2 and Q3 [4][8]. - Operating cash flows generated YTD amounted to $25 million [8]. Production and Operational Highlights - Average corporate production for Q3 2025 was 4,214 barrels of oil equivalent per day (boe/d), a 12% increase from Q2 2025 [10][11]. - The company drilled two development wells in Carrizales Norte and one exploration well in Mateguafa Oeste during Q3 2025 [8][10]. - The Mateguafa Attic discovery is expected to become a major production platform, with further drilling planned for Q1 2026 at the Icaco prospect [6][7]. Cost and Pricing Insights - Realized corporate oil operating netbacks were $38.21 per barrel for Q3 2025, down from $52.00 in Q3 2024 [12][13]. - The company experienced a reduction in realized prices for crude oil and natural gas compared to the same period in 2024, with crude oil prices averaging $56.67 per barrel in Q3 2025 [12][15]. - Operating costs decreased significantly in Q3 2025 compared to Q2 2025, attributed to investments in infrastructure [7][15]. Regulatory and Future Plans - Arrow is in discussions with authorities regarding the extension of the Tapir block and the termination of obligations for the COR-39 Block [5][7]. - The company plans to continue drilling low-risk wells at the Mateguafa Attic pad and prepare for exploratory drilling at the Icaco prospect [9][10].

Core Insights - Champion Homes, Inc. reported a net sales increase of 11.0% to $684.4 million for the second quarter of fiscal 2026 compared to the same period in fiscal 2025 [1] - The number of U.S. homes sold rose by 3.4% to 6,575 units [1] - The backlog of orders increased by 3.5% to $313.2 million from the previous quarter of fiscal 2026 [1] - The average selling price (ASP) per U.S. home was noted but not specified in the provided text [1]

Core Insights - Vistin Pharma ASA reported a revenue increase in Q3 2025, reaching MNOK 109, up from MNOK 106 in Q3 2024, driven by a 10% higher sales volume [1] - Year-to-date revenue for 2025 is MNOK 342, an 8% increase from MNOK 316 in the same period last year [1] - The company's EBITDA for Q3 2025 was MNOK 28, slightly down from MNOK 29 in Q3 2024, impacted by lower global metformin prices [1] - Year-to-date EBITDA for 2025 stands at MNOK 89, a 16% increase from MNOK 77 in YTD 2024 [1] - Net profit for Q3 2025 was MNOK 18.5, compared to MNOK 16.6 in the previous year [2] - The company achieved an all-time high production volume of 1,600 MT of metformin in the quarter [2] Financial Performance - Q3 2025 revenue: MNOK 109, up 2.8% from Q3 2024 [1] - YTD 2025 revenue: MNOK 342, an 8% increase from YTD 2024 [1] - Q3 2025 EBITDA: MNOK 28, down from MNOK 29 in Q3 2024 [1] - YTD 2025 EBITDA: MNOK 89, up 16% from YTD 2024 [1] - Q3 2025 net profit: MNOK 18.5, compared to MNOK 16.6 in Q3 2024 [2] Production and Operations - All-time high production volume of metformin: 1,600 MT in Q3 2025 [2]